All In MedTech

FDA Clearance Tracker · P240011-S010

Altaviva™

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 13, 2026

Approved

Time to decision

144 days

Received Feb 19, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P240011-S010
Device name
Altaviva™
Applicant location
Minneapolis, MN
Received
Feb 19, 2026
Decided
Jul 13, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P240011

Device type

Device class
Class III

Every decision under product code QPT

FDA's approval statement

As written in FDA's record.

Approval of updated labeling for the Altaviva™ system to incorporate the 24-month results from the TITAN 2 clinical study.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.